Quick Answer
BridgeBio Pharma, Inc. reported Operating Income Loss of -$523.41 million for the year ending 2025.
- BridgeBio Pharma, Inc. showed an increase of +11.7% in Operating Income Loss from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$41.46 million | Q1 2019: -$63.75 million | Q2 2019: -$69.32 million | Q3 2019: -$54.53 million | Q1 2020: -$102.49 million | Q2 2020: -$124.57 million | Q3 2020: -$119.94 million | Q1 2021: -$167.50 million | Q2 2021: -$94.02 million | Q3 2021: -$149.50 million | Q1 2022: -$173.68 million | Q2 2022: -$80.18 million | Q3 2022: -$129.12 million | Q1 2023: -$126.16 million | Q2 2023: -$146.10 million | Q3 2023: -$157.69 million | Q1 2024: $343.0 thousand | Q2 2024: -$175.54 million | Q3 2024: -$191.75 million | Q1 2025: -$104.37 million | Q2 2025: -$134.28 million | Q3 2025: -$145.20 million.
- Over the full 9 years of available data (2017 to 2025), BridgeBio Pharma, Inc.'s Operating Income Loss has declined by 1,093.4%.
- Historical annual values: Fiscal year 2025: -$523.41 million | Fiscal year 2024: -$592.97 million | Fiscal year 2023: -$607.37 million | Fiscal year 2022: -$512.20 million | Fiscal year 2021: -$576.63 million | Fiscal year 2020: -$474.48 million | Fiscal year 2019: -$266.24 million | Fiscal year 2018: -$183.66 million | Fiscal year 2017: -$43.86 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: